How many drugs treat Glioma, malignant?

Drug Landscape tracks 4 marketed treatments for Glioma, malignant (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/glioma-malignant.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Glioma, malignant — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glioma, malignant (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Glioma, malignant, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Temodar	temozolomide	Merck & Co.	Alkylating Drug [EPC]		1999-01-01
Gliadel	CARMUSTINE	Avet Lifesciences	Alkylating Drug	Glutathione reductase, mitochondrial	1977-01-01
Carmustin	Carmustin	University Hospital Freiburg		Glutathione reductase, mitochondrial
Temodal	Temodal	Armando Santoro, MD

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Armando Santoro, MD · 1 drug in Glioma, malignant
Avet Lifesciences · 1 drug in Glioma, malignant
Merck & Co. · 1 drug in Glioma, malignant
University Hospital Freiburg · 1 drug in Glioma, malignant

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Glioma, malignant:

Cite this brief

Drug Landscape (2026). Glioma, malignant — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/glioma-malignant. Accessed 2026-06-10.

Glioma, malignant full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing